Project Details
| Status | Active |
|---|---|
| Effective start/end date | 23/06/26 → 22/06/31 |
Clinical Trial Phase
- Phase III (a & b)
A Randomised, Open label, Phase III Study of AZD5335 versus Mirvetuximab Soravtansine in FRα-high and AZD5335 versus Investigator’s Choice Chemotherapy in FRα low Expressing High grade Platinum resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)
- Frentzas, Sophia (Primary Chief Investigator (PCI))
Project: Research